ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1697

Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 64 Weeks: Long-term Results from the Japanese Subgroup in a Phase III Study

Mitsuhiro Takeno1, Yoshiya Tanaka 2, Hajime Kono 3, Shoji Sugii 4, Mitsumasa Kishimoto 5, Sue Cheng 6, Shannon McCue 7, Mindy Chen 8, Maria Paris 6 and Hiroaki Dobashi 9, 1Nippon Medical School, Tokyo, Japan, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Teikyo University School of Medicine, Tokyo, Japan, 4Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, Japan, 5Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, 6Celgene Corporation, Summit, 7Celgene Corporation, Summit, NJ, 8Celgene Corporation, Berkeley Heights, NJ, 9Kagawa University, Kagawa, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Behcet's syndrome, clinical trials, Japanese and ulcers

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Behçet’s syndrome is a chronic, multi-system, variable vessel vasculitis characterized by painful, recurrent oral ulcers (OU) that can be disabling and may impair quality of life. Apremilast (APR), an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in the treatment of OU of Behçet’s syndrome in a phase III, multinational, randomized, double-blind, placebo (PBO)-controlled study (RELIEF). Here, we report efficacy and safety of APR assessed over 64 weeks in the subgroup of Japanese patients in RELIEF.

Methods: Patients were randomized (1:1) to APR 30 mg BID or PBO BID for a 12-week PBO-controlled phase, followed by a 52-week active treatment extension. Patients were stratified by region (Japan/other). Eligible patients were ≥18 years of age, had active Behçet’s syndrome, with ≥3 OU at randomization or ≥2 OU at screening and randomization and without active major organ involvement. The primary efficacy endpoint was area under the curve for the number of OU over 12 weeks (AUCWk0-12). Clinical improvement in OU was evaluated by assessments of OU number and pain (100 mm visual analog scale), disease activity (Behçet’s Disease Current Activity Form [BDCAF], composed of the Behçet’s Disease Current Activity Index [BDCAI] and Patient’s and Clinician’s Perception of Disease Activity, and Behçet’s Syndrome Activity Score [BSAS]) over 64 weeks. An ANCOVA model was used to analyze the primary endpoint. In the Japanese subgroup, Week 12 variables were prespecified without multiplicity adjustment. Nominal P values are given. Data at Week 64 are as observed.

Results: Of the 207 randomized patients, 39 were Japanese (APR: n=19; PBO: n=20); 26 Japanese patients completed the active treatment phase (12 initially randomized to APR and 14 initially randomized to PBO). Consistent with the findings of the overall study population, the primary endpoint of AUCWk0-12 was significantly lower for APR vs PBO (115.9 vs 253.3; nominal P=0.0168). At Week 12, significantly more Japanese patients had OU complete response with APR (57.9%) vs PBO (25.0%) (nominal P=0.0426); numerically greater reductions in OU pain were observed with APR vs PBO (−17.0 [95% CI: −39.1, 5.1]; nominal P=0.1273). Improvements in mean number of OU (Figure 1), OU pain (Figure 2), complete and partial response rates, as well as disease activity assessments (BDCAF and BSAS) were observed at Week 12 and generally maintained in Japanese patients continuing APR 30 mg BID treatment for up to 64 weeks and emerged in those who switched from PBO to APR. At 4 weeks after APR treatment discontinuation, worsening in measures of oral ulcer disease was observed in both treatment groups. Adverse event (AE) rates were similar in the 2 groups during the PBO-controlled period (APR: 73.7%; PBO: 75.0%). Common AEs were diarrhea, upper respiratory tract infection, nausea, and headache. No new safety concerns were identified up to 64 weeks.

Conclusion: APR demonstrated efficacy in the treatment of OU in a subset of Japanese patients with Behçet’s syndrome from RELIEF. Benefits were sustained up to 64 weeks with continued APR treatment. Safety findings were consistent with the known AE profile of APR.


Disclosure: M. Takeno, Celgene Corporation, 5, Mitsubishi-Tanabe, 8; Y. Tanaka, Abbvie, 8, AbbVie, 5, 8, Asahi-kasei, 2, Asahi-Kasei, 2, Asahi-kasei, BMS, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, Ono, Pfizer, Sanofi, Takeda, UCB, 2, Astellas, 8, Astellas Pharma, 9, Astellas Pharma, Inc., 2, 3, 5, 8, 9, Astellas, BMS, Chugai, Daiichi-Sankyo, Eli Lilly, Janssen, Mitsubishi-Tanabe, Pfizer, Sanofic, UCB, YL Biologics, 8, BMS, 2, 5, 8, Bristol-Myers, 2, 8, Bristol-Myers Squibb, 2, 8, Chugai, 2, 8, Daiichi-Sankyo, 2, 8, Daiichi-Sankyo, Astellas, Eli Lilly, Chugai, Sanofi, Abbvie, Pfizer, YL Biologics, Bristol-Myers, 8, Eisai, 2, 8, Eli Lilly, 5, 8, Eli Lilly and Company, 8, Genzyme, 5, Glaxo-Smithkline, UCB, Mitsubishi-Tanabe, Novartis, Eisai, Takeda, Janssen, Asahi-kasei, 8, Janssen, 8, Mitsubishi-Tanabe, 2, 8, Mitsubishi-Tanabe, Bristol-Myers, Eisai, Chugai, Takeda, Abbvie, Astellas, Daiichi-Sankyo, Ono, MSD, Taisho-Toyama., 2, Mitsubishi-Tanabe, Takeda, Daiichi-Sankyo, Chugai, Bristol-Myers, MSD, Astellas, Abbvie, Eisai, 2, Novartis, 8, Ono, 2, Pfizer, 5, 8, Pfizer Inc, 8, Roche, 5, Sanofi, 2, Takeda, 2, 8, Teijin, 8, UCB, 2, YL Biologics, 8; H. Kono, Celgene Corporation, 2; S. Sugii, None; M. Kishimoto, AbbVie, 8; S. Cheng, Celgene Corporation, 3; S. McCue, Celgene Corporation, 3; M. Chen, Celgene Corporation, 3; M. Paris, Celgene Corporation, 3; H. Dobashi, None.

To cite this abstract in AMA style:

Takeno M, Tanaka Y, Kono H, Sugii S, Kishimoto M, Cheng S, McCue S, Chen M, Paris M, Dobashi H. Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 64 Weeks: Long-term Results from the Japanese Subgroup in a Phase III Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-apremilast-for-oral-ulcers-associated-with-active-behcets-syndrome-over-64-weeks-long-term-results-from-the-japanese-subgroup-in-a-phase-iii-study/. Accessed January 21, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-apremilast-for-oral-ulcers-associated-with-active-behcets-syndrome-over-64-weeks-long-term-results-from-the-japanese-subgroup-in-a-phase-iii-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.